Early and effective treatment of cancers could mean the difference between life and death. Therefore, companion diagnostics and biomarker discovery could be considered one of the most important avenues to explore in immuno-oncology.

What is the future of precision medicine for immuno-oncology, and how can we achieve it? In this Insight Article, we sat down with senior representatives from the University of Michigan, the Beth Israel Deaconess Medical Center / Harvard Medical School, and The Institute of Cancer Research, London, to discover more about harnessing the potential of spatial biology and predictive biomarkers to achieve targeted results.